PMID- 21327436
OWN - NLM
STAT- MEDLINE
DCOM- 20121207
LR  - 20221207
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Print)
IS  - 0172-8172 (Linking)
VI  - 32
IP  - 6
DP  - 2012 Jun
TI  - Safety and effectiveness responses to etanercept for rheumatoid arthritis in 
      Japan: a sub-analysis of a post-marketing surveillance study focusing on the 
      duration of rheumatoid arthritis.
PG  - 1511-9
LID - 10.1007/s00296-010-1784-8 [doi]
AB  - The aim is to investigate the relationship of duration of rheumatoid arthritis 
      (RA) with safety and effectiveness of etanercept (ETN) in Japan. Post-marketing 
      surveillance data for 7,099 patients treated with ETN were analyzed. Baseline 
      characteristics, treatment effectiveness, incidence of adverse events (AEs), and 
      serious AEs (SAEs) in relation to duration of RA were studied. At baseline, 
      patients with RA for longer duration were older, weighed less, had more 
      comorbidities, allergies, and corticosteroid use, but smoked less and had less 
      morning stiffness. By 2-5 years with RA, more than half of the patients had 
      advanced to Steinbrocker radiographic stage III or IV. Methotrexate (MTX) was the 
      most commonly used pre-treatment disease-modifying antirheumatic drug; however, 
      concomitant MTX use and its dose were lower among patients with longer duration 
      of RA. Remission rates (26.6%) were greatest among patients having RA for 
      <2 years. Less AEs and SAEs were observed among patients with shorter duration of 
      RA. These results suggest that RA treatment in Japan in the era pre-biologics may 
      not have been adequate to control disease activity and prevent joint destruction. 
      Patients with shorter duration of RA may have better physical status which allows 
      the opportunity to treat more intensively putting a higher percentage of patients 
      in remission and possibly decreasing exposure to SAEs.
FAU - Koike, Takao
AU  - Koike T
AD  - Hokkaido University Graduate School of Medicine, Sapporo, Japan.
FAU - Harigai, Masayoshi
AU  - Harigai M
FAU - Inokuma, Shigeko
AU  - Inokuma S
FAU - Ishiguro, Naoki
AU  - Ishiguro N
FAU - Ryu, Junnosuke
AU  - Ryu J
FAU - Takeuchi, Tsutomu
AU  - Takeuchi T
FAU - Tanaka, Yoshiya
AU  - Tanaka Y
FAU - Yamanaka, Hisashi
AU  - Yamanaka H
FAU - Fujii, Koichi
AU  - Fujii K
FAU - Yoshinaga, Takunari
AU  - Yoshinaga T
FAU - Freundlich, Bruce
AU  - Freundlich B
FAU - Suzukawa, Michio
AU  - Suzukawa M
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20110216
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Antirheumatic Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/diagnosis/*drug therapy/ethnology
MH  - Asian People
MH  - Chi-Square Distribution
MH  - Drug Substitution
MH  - Drug Therapy, Combination
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/adverse effects/*therapeutic use
MH  - Japan/epidemiology
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Product Surveillance, Postmarketing
MH  - Proportional Hazards Models
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC3364409
EDAT- 2011/02/18 06:00
MHDA- 2012/12/12 06:00
PMCR- 2011/02/16
CRDT- 2011/02/18 06:00
PHST- 2010/09/20 00:00 [received]
PHST- 2010/12/30 00:00 [accepted]
PHST- 2011/02/18 06:00 [entrez]
PHST- 2011/02/18 06:00 [pubmed]
PHST- 2012/12/12 06:00 [medline]
PHST- 2011/02/16 00:00 [pmc-release]
AID - 1784 [pii]
AID - 10.1007/s00296-010-1784-8 [doi]
PST - ppublish
SO  - Rheumatol Int. 2012 Jun;32(6):1511-9. doi: 10.1007/s00296-010-1784-8. Epub 2011 
      Feb 16.